Evidence map›Paper›PMID 29218029›Full record

ArticleFrontiers in endocrinology2017

Microvascular Complications in Type 1 Diabetes: A Comparative Analysis of Patients Treated with Autologous Nonmyeloablative Hematopoietic Stem-Cell Transplantation and Conventional Medical Therapy.

Jaquellyne G Penaforte-Saboia, Renan M Montenegro, Carlos E Couri, Livia A Batista, Ana Paula D R Montenegro, Virginia O Fernandes, Hussain Akhtar, Carlos A Negrato, Kelen Cristina Ribeiro Malmegrim, Daniela Aparecida Moraes and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Jaquellyne G Penaforte-SaboiaPost Graduate Program in Medical Sciences, Federal University of Ceará, Ceará, Brazil.
Renan M MontenegroPost Graduate Program in Medical Sciences, Federal University of Ceará, Ceará, Brazil.
Carlos E CouriCenter for Cell-Based Therapy, Regional Blood Center of Ribeirão Preto, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Livia A BatistaPost Graduate Program in Medical Sciences, Federal University of Ceará, Ceará, Brazil.
Ana Paula D R MontenegroFederal University of Ceará, Ceará, Brazil.
Virginia O FernandesFederal University of Ceará, Ceará, Brazil.
Hussain AkhtarFederal University of Ceará, Ceará, Brazil.
Carlos A NegratoBrazilian Society of Diabetes, São Paulo, Brazil.
Kelen Cristina Ribeiro MalmegrimCenter for Cell-Based Therapy, Regional Blood Center of Ribeirão Preto, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Daniela Aparecida MoraesCenter for Cell-Based Therapy, Regional Blood Center of Ribeirão Preto, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Juliana B E DiasCenter for Cell-Based Therapy, Regional Blood Center of Ribeirão Preto, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Belinda P SimõesCenter for Cell-Based Therapy, Regional Blood Center of Ribeirão Preto, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Marilia Brito GomesState University of Rio de Janeiro, Rio de Janeiro, Brazil.
Maria Carolina OliveiraCenter for Cell-Based Therapy, Regional Blood Center of Ribeirão Preto, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Universidade Federal do Ceará · BRUniversidade de São Paulo · BRClinics Hospital of Ribeirão Preto · BRSociedade Brasileira de Diabetes · BRUniversidade do Estado do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore the impact on microvascular complications, long-term preservation of residual B-cell function and glycemic control of patients with type 1 diabetes treated with autologous nonmyeloablative hematopoietic stem-cell transplantation (AHST) compared with conventional medical therapy (CT). RESEARCH DESIGN AND

methodsCross-sectional data of patients treated with AHST were compared with patients who received conventional therapy from the Brazilian Type 1 Diabetes Study Group, the largest multicenter observational study in type 1 diabetes mellitus in Brazil. Both groups of patients had diabetes for 8 years on average. An assessment comparison was made on the presence of microvascular complications, residual function of B cell, A1c, and insulin dose of the patients.

resultsAfter a median of 8 years of diagnosis, none of the AHST-treated patients (

conclusionPatients with newly diagnosed type 1 diabetes treated with AHST presented lower prevalence of microvascular complications, higher residual B-cell function, and better glycemic control compared with the CT group.

Indexed as

autologous nonmyeloablative hematopoietic stem-cell transplantationglycemic controlmicrovascular complicationsresidual B-cell functiontype 1 diabetes

Identifiers

PMID29218029
PMCPMC5703738
OpenAlexW2770967178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.